A new experimental fat jab could rival blockbuster weight-loss drugs such as Wegovy and Mounjaro, a study has found.
uncertain
study → rival → Wegovy
In a trial, the once-weekly injection ribupatide helped patients shed an average of 17.7 per cent of their body weight – almost a fifth – in just 11 months.
asserted
patients → help → months
Half of those on the highest dose of the drug, developed by a Chinese pharmaceutical company, lost more than a fifth of their starting weight.
asserted
Half → develop → weight
And participants on the two highest doses, meanwhile, were still losing weight when the study ended.
asserted
study → lose → weight
By comparison, Wegovy, which contains the active ingredient semaglutide, has been shown to help patients lose around 18.7 per cent of their weight after 72 weeks – roughly 16-and-a-half months.
asserted
patients → contain → weeks
Mounjaro, another blockbuster jab made with tirzepatide, produces weight loss of around 22.5 per cent over the same 72-week period.
asserted
Mounjaro → make → period
While the drugs have not been directly compared, the findings suggest ribupatide could become a powerful weight loss injection to rival those already on the market.
uncertain
ribupatide → compare → market
The findings come just months after patients were recruited for phase three trials of the drug in Britain.
asserted
patients → come → Britain
A new experimental fat jab could rival blockbuster weight-loss drugs such as Wegovy and Mounjaro, a study has found
Ribupatide works like Mounjaro, mimicking two hormones that help to control appetite and blood sugar.
This helps people feel fuller for longer, reducing hunger and helping them eat less.
uncertain
them → rival → less
In the latest study, published in the journal JAMA, researchers from Fudan University in Shanghai recruited 567 overweight or obese adults, with an average age of 34, to test the drug.
asserted
researchers → publish → drug
Of those, 424 participants were randomly assigned to receive weekly injections of ribupatide at doses of 2mg, 4mg or 6mg, while the remaining 143 received a dummy placebo treatment.
asserted
143 → assign → treatment
After 48 weeks, patients given the lowest dose lost an average of 10.7 per cent of their body weight.
asserted
patients → give → weight
Those on the middle dose shed 16.4 per cent, while those taking the highest dose lost 17.7 per cent.
asserted
those → shed → cent
By contrast, those given the dummy injection lost just 1.4 per cent.
asserted
those → give → cent
Some patients even saw far greater weight loss.
asserted
patients → see → loss
Around 13.6 per cent of the 142 patients taking the 2mg dose lost at least a fifth of their body weight, rising to 37.1 per cent of the 141 taking 4mg and 44.4 per cent of the 141 taking 6mg.
asserted
cent → take → mg
Intriguingly, the researchers suggested the drug's full potential may not yet have been reached.
uncertain
potential → suggest → ?
'Reductions in body weight at week 48 were 16.4 per cent and 17.7 per cent with ribupatide 4mg and 6mg, respectively, and weight loss had not clearly plateaued in either group,' they wrote.
asserted
they → plateaue → group
For people taking the drugs, weight loss typically slows over time because the body burns fewer calories as it gets smaller.
asserted
it → take → calories
Like other weight-loss jabs, which are taken by around 2.5 million Britons, the most common side effects were stomach and digestive problems.
asserted
effects → take → Britons
These symptoms, which included nausea, vomiting and diarrhoea, affected around half of people on the lowest dose and around two-thirds on the highest dose.
asserted
which → include → dose
The jab also appeared to offer benefits beyond weight loss, with researchers finding improvements in measurements like blood pressure, blood sugar control and cholesterol.
asserted
researchers → appear → pressure
Around 14 million adults in the UK have high blood pressure, which can increase the risk of deadly conditions such as heart failure.
asserted
which → have → failure
Meanwhile, having good blood sugar control can help prevent type 2 diabetes and reducing cholesterol can lower the risk of stroke.
asserted
reducing → have → stroke
Systolic blood pressure – the top number in a reading – fell by around seven to nine points more than among patients given the dummy injection.
asserted
pressure → fall → injection
Meanwhile, triglycerides, a type of fat found in the blood that can cause serious health problems when levels become too high, fell by around 29 to 37 per cent more than the placebo.
asserted
levels → find → placebo
The drug also appeared to help the body respond better to insulin, the hormone that helps control blood sugar levels.
asserted
that → appear → levels
Those on the 2mg dose had a 30 per cent reduced resistance to insulin, rising to 44 per cent at 4mg and 46 per cent at 6mg.
asserted
Those → have → mg
Total cholesterol levels also reduced by 6 per cent at 2mg, 9 per cent at 4mg and 8 per cent at 6mg.
asserted
levels → reduce → mg
Furthermore, waist size, which can indicate levels of visceral fat – the harmful fat stored deep inside the abdomen around vital organs – fell.
asserted
which → indicate → organs
Measurements shrank by an average of around 9cm to 14cm among those taking ribupatide, compared with just 2.5cm in the dummy treatment group.
Despite the encouraging findings, the researchers cautioned that the study had several limitations.
asserted
study → shrink → limitations
'First, the 48-week treatment period may not have captured the full weight loss effect of ribupatide 4mg and 6mg,' they wrote.
uncertain
they → capture → ribupatide
'
The results come three months after clinical trials began recruiting patients in cities including Manchester, London and Nottingham to test the drug.
asserted
trials → come → drug
Researchers said they would compare weekly ribupatide injections of up to 10mg with a placebo over an 18-month period in people with and without diabetes.
asserted
they → say → diabetes
Ribupatide is also being compared directly with semaglutide in a separate trial involving around 1,200 people across the UK and several other countries.
asserted
Ribupatide → compare → UK